Insilico Medicine completed an oversubscribed Hong Kong IPO and immediately converted that momentum into a multiyear oncology R&D collaboration with Servier. The company priced its listing and raised roughly $292 million, signaling investor appetite for AI-first drug discovery platforms. Insilico will use the IPO proceeds to expand clinical R&D and develop generative AI models while Servier will lead clinical validation, regulatory interactions and worldwide commercialization of candidates arising from the collaboration. Servier and Insilico disclosed an agreement structure that includes up to $888 million in potential payments and $32 million in near-term R&D funding. The sequence — public financing followed by a sizable pharma partnership — underscores the sector’s emphasis on de‑risking AI discovery through cash and integrated development deals. Alex Zhavoronkov, Insilico’s founder and CEO, framed the move as platform validation and a step toward advancing oncology candidates into the clinic.